Weersuntinib

威顺替尼

Report date: 2024/08/21 20:00:59
NME

Base Information

Drug NameWeersuntinib
Drug Alias NameLS-01
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProtein disulfide isomerase inhibitors
TargetsProtein disulfide isomerase
Therapy Area/IndicationsSolid tumoursCachexiaEsophageal Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesGuangzhou Liushun Biological Technology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesGuangzhou Liushun Biological Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursCachexiaEsophageal Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A